Rapamycin — From Easter Island to Longevity Clinics
Discovered in soil, 10,000 km from nowhere
Rapamycin (sirolimus) is produced by a bacterium found in Easter Island soil in 1964 — the island's Polynesian name is Rapa Nui, hence rapamycin. Originally developed as an antifungal, it was later found to suppress the immune system and discovered to extend lifespan in virtually every model organism tested.
The most replicable longevity drug in history
Rapamycin extends lifespan in yeast, worms, flies, and mice. The 2009 NIA Interventions Testing Program showed it extended mouse lifespan even when started in middle age — the first intervention to do so. The effect has been replicated in multiple labs and multiple strains.
Human off-label use is now common
Rapamycin is FDA-approved for transplant rejection and certain cancers, not for longevity. But off-label prescription for healthspan purposes has grown fast since ~2020, with intermittent dosing (weekly, not daily) aimed at autophagy + immune function benefits while minimising side effects.
True or False
Rapamycin suppresses the immune system at all doses.
What human evidence exists
The 2014 Everolimus-in-elderly trial showed improved vaccine response at a rapamycin-analogue dose. Multiple longevity-clinic observational cohorts report improvement in inflammation markers, body composition, and periodontal disease. No randomised all-cause-mortality human trial exists yet — the evidence bar for that is high.
Key Takeaway
Rapamycin has the deepest + most replicated longevity evidence base of any drug. It's on-market, inexpensive, and being prescribed off-label. It's also a real pharmaceutical with real side effects. Thoughtful, physician-monitored use is now a reasonable conversation for informed adults.